Aspirin Responsiveness in Women at Risk for Cardiac Events

Completed · Phase 4

Conditions studied: Heart Disease

In brief

The objective of this pilot study is to evaluate the prevalence of biological aspirin resistance in women at risk for CHD taking low dose (81 mg) aspirin. Aspirin responsiveness will be measured with the VerifyNow device (Accumetrics; San Diego, CA). Those women identified as biologically resistant will be switched to aspirin 325 mg for 14 days and then re-tested for aspirin responsiveness.

Key facts

Study ID

NCT00818337

Run by

Creighton University

People needed

36

Starts

2008-11-01

Expected to finish

2009-06-01

Last updated by the study team

2012-12-04

Who can join

Age: 19 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Women at least 19 years old
• Taking 81 mg aspirin daily, non-enteric coated, for at least one month for the primary prevention of cardiovascular disease.
• Able and willing to provide informed consent

You may not qualify if…

• Pregnancy or breastfeeding
• Known CHD
• Currently taking clopidogrel or ticlopidine
• Use of heparin, warfarin, or glycoprotein IIb/IIIa inhibitors within previous 96 hours
• Allergy or hypersensitivity to salicylates
• Use of other OTC or prescription analgesics or anti-inflammatory medication in the past two weeks
• Currently participating in another investigational drug or device study

Where it is running

• The Cardiac Center at Creighton University — Omaha, Nebraska, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.